RElugolix VErsus LeUprolide Cardiac Trial

Summary

RElugolix VErsus LeUprolide Cardiac Trial is a clinical trial^[1].

Key Facts

• RElugolix VErsus LeUprolide Cardiac Trial is in the country of United States^[2].
• RElugolix VErsus LeUprolide Cardiac Trial's instance of is recorded as clinical trial^[3].
• RElugolix VErsus LeUprolide Cardiac Trial's start time is recorded as +2022-06-06T00:00:00Z^[4].
• RElugolix VErsus LeUprolide Cardiac Trial's end time is recorded as +2024-04-29T00:00:00Z^[5].
• RElugolix VErsus LeUprolide Cardiac Trial's main subject is recorded as carcinoma^[6].
• RElugolix VErsus LeUprolide Cardiac Trial's number of participants is recorded as {'unit': '1', 'amount': '+90'}^[7].
• RElugolix VErsus LeUprolide Cardiac Trial's title is recorded as Mechanism and Predictors of Cardiotoxicity After Prostate Cancer Treatment: A Parallel Cohort and Randomized Trial Comparing Radiation Alone, Radiation Plus Leuprolide, and Radiation Plus Relugolix^[8].
• RElugolix VErsus LeUprolide Cardiac Trial's short name is recorded as REVELUTION^[9].
• RElugolix VErsus LeUprolide Cardiac Trial's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• RElugolix VErsus LeUprolide Cardiac Trial's ClinicalTrials.gov ID is recorded as NCT05320406^[11].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as leuprolide^[12].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as relugolix^[13].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as female fertility agents^[14].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as fertility medication^[15].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as reproductive control agents^[16].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as hormonal antineoplastic agent^[17].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as alkylating antineoplastic agent^[18].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as antiandrogen^[19].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as hormone antagonist^[20].
• RElugolix VErsus LeUprolide Cardiac Trial's research intervention is recorded as hormones, hormone substitutes, and hormone antagonists^[21].
• RElugolix VErsus LeUprolide Cardiac Trial's clinical trial phase is recorded as phase IV clinical trial^[22].
• RElugolix VErsus LeUprolide Cardiac Trial's research site is recorded as Emory University^[23].
• RElugolix VErsus LeUprolide Cardiac Trial's research subject recruitment status is recorded as recruiting^[24].
• RElugolix VErsus LeUprolide Cardiac Trial's study type is recorded as interventional study^[25].